NASDAQ:APMD Apnimed Q3 2026 Earnings Results & Report $17.38 +1.10 (+6.76%) As of 01:40 PM Eastern Apnimed reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$1.05, while revenue was $2.48 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call8:00 AM ET Apnimed EPS ResultsActual EPS-$1.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AApnimed Revenue ResultsActual Revenue$2.48 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Apnimed Q3 2026 Earnings FAQ Did Apnimed beat earnings estimates for Q3 2026? Apnimed (NASDAQ:APMD) reported earnings of -$1.05 per share for Q3 2026. The report was announced on Monday, November 16, 2026. What was Apnimed's revenue for Q3 2026? Apnimed reported revenue of $2.48 million for Q3 2026. Apnimed Earnings HeadlinesApnimed, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 16 at 1:23 PM | marketscreener.comMApnimed Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 16 at 8:00 AM | globenewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)Apnimed, Inc. (NASDAQ:APMD) Stock Has Average Target Price of $50.33 According to AnalystsNovember 16 at 1:33 AM | americanbankingnews.comApnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A BuyNovember 12, 2026 | seekingalpha.comApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 5, 2026 | globenewswire.comSee More Apnimed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Apnimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apnimed and other key companies, straight to your email. Email Address About ApnimedApnimed (NASDAQ:APMD) is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment. Apnimed is based in Cambridge, Massachusetts. Its research and development efforts are centered on advancing pharmaceutical treatments for sleep apnea and related conditions.View Apnimed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.